- Home
- GCTK vs SILO Comparison
GCTK vs SILO Comparison
Compare GCTK & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GCTK | SILO |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Medical/Dental Instruments | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GCTK | SILO |
|---|---|---|
| Price | $3.86 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 75.9K | ★ 186.2K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.21 | $0.33 |
| 52 Week High | $229.44 | $3.37 |
Technical Indicators
Market Signals| Indicator | GCTK | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 46.95 |
| Support Level | $3.21 | $0.33 |
| Resistance Level | $4.21 | $0.43 |
| Average True Range (ATR) | 0.40 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 30.03 | 57.14 |
Price Performance
Historical ComparisonAbout GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.